Glenmark Pharmaceuticals has been granted a patent for hetero-dimeric immunoglobulins targeting human CD3 and CD38 antigens. The patent includes specific antibody sequences for therapeutic and diagnostic applications, detailing the variable regions of both heavy and light chains necessary for binding to the CD38 antigen. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of June 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Hetero-dimeric immunoglobulins targeting cd3 and cd38 antigens
The granted patent US12006367B2 outlines a novel antibody or its fragment that specifically binds to human CD38, detailing specific amino acid sequences for the heavy and light chain variable regions. The claims specify the complementarity-determining regions (CDRs) of the antibody, with particular sequences identified as SEQ ID NOs 25-30, 52, 55, 58-61, 73, 74, 75, 76, 145, 146, 147, 148, and 149. The patent also encompasses various forms of the antibody, including murine, chimeric, and humanized antibodies, as well as those with heavy and light chain variable region sequences that exhibit at least 80% identity to the specified sequences.
Additionally, the patent claims include a composition containing the antibody and a pharmaceutically acceptable carrier, as well as an immunoconjugate that links the antibody to a therapeutic agent. The therapeutic applications of the antibody are highlighted, particularly in treating malignant hematological diseases such as multiple myeloma, various forms of leukemia, and lymphoma. The claims further specify that the antibody can bind to both human and cynomolgus CD38, indicating its potential for broader therapeutic use.
To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
